DaVita Inc. (NYSE:DVA) Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. raised its holdings in DaVita Inc. (NYSE:DVA) by 1.8% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 126,071 shares of the company’s stock after acquiring an additional 2,186 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in DaVita were worth $20,667,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Transcendent Capital Group LLC purchased a new stake in shares of DaVita during the 3rd quarter worth $25,000. Blue Trust Inc. increased its stake in DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares during the period. Family Firm Inc. acquired a new position in DaVita in the second quarter valued at $43,000. Versant Capital Management Inc increased its stake in DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after purchasing an additional 155 shares during the period. Finally, Friedenthal Financial acquired a new position in shares of DaVita during the second quarter worth about $48,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. This trade represents a 5.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Joel Ackerman sold 64,029 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the transaction, the chief financial officer now owns 111,481 shares in the company, valued at approximately $17,286,243.86. The trade was a 36.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 156,086 shares of company stock worth $24,807,161 in the last ninety days. 2.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Truist Financial boosted their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Barclays boosted their price objective on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Bank of America boosted their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. UBS Group boosted their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Finally, TD Cowen upped their price target on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, DaVita has a consensus rating of “Hold” and a consensus target price of $161.80.

DaVita Price Performance

Shares of DVA stock opened at $160.33 on Monday. The company has a market capitalization of $13.15 billion, a PE ratio of 17.30, a price-to-earnings-growth ratio of 0.90 and a beta of 0.89. The firm has a fifty day simple moving average of $157.78 and a 200-day simple moving average of $147.61. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. DaVita Inc. has a twelve month low of $92.68 and a twelve month high of $168.50.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter last year, the company posted $2.85 earnings per share. DaVita’s revenue for the quarter was up 4.6% compared to the same quarter last year. Equities research analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.